Sartorius Stedim Biotech Stock Cash And Equivalents
| DIM Stock | EUR 208.20 2.20 1.07% |
Sartorius Stedim Biotech fundamentals help investors to digest information that contributes to Sartorius Stedim's financial success or failures. It also enables traders to predict the movement of Sartorius Stock. The fundamental analysis module provides a way to measure Sartorius Stedim's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sartorius Stedim stock.
Sartorius |
Sartorius Stedim Biotech Company Cash And Equivalents Analysis
Sartorius Stedim's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Sartorius Stedim Cash And Equivalents | 161.7 M |
Most of Sartorius Stedim's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sartorius Stedim Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Sartorius Stedim Biotech has 161.7 M in Cash And Equivalents. This is 80.3% lower than that of the Healthcare sector and 48.5% lower than that of the Medical Instruments & Supplies industry. The cash and equivalents for all France stocks is 94.02% higher than that of the company.
Sartorius Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sartorius Stedim's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sartorius Stedim could also be used in its relative valuation, which is a method of valuing Sartorius Stedim by comparing valuation metrics of similar companies.Sartorius Stedim is currently under evaluation in cash and equivalents category among related companies.
Sartorius Fundamentals
| Return On Equity | 0.41 | |||
| Return On Asset | 0.15 | |||
| Profit Margin | 0.25 % | |||
| Operating Margin | 0.32 % | |||
| Current Valuation | 31.28 B | |||
| Shares Outstanding | 92.17 M | |||
| Shares Owned By Insiders | 73.81 % | |||
| Shares Owned By Institutions | 13.83 % | |||
| Price To Earning | 80.53 X | |||
| Price To Book | 13.32 X | |||
| Price To Sales | 8.58 X | |||
| Revenue | 3.49 B | |||
| Gross Profit | 1.83 B | |||
| EBITDA | 1.33 B | |||
| Net Income | 1.13 B | |||
| Cash And Equivalents | 161.7 M | |||
| Cash Per Share | 1.75 X | |||
| Total Debt | 1.02 B | |||
| Debt To Equity | 0.50 % | |||
| Current Ratio | 1.49 X | |||
| Book Value Per Share | 26.58 X | |||
| Cash Flow From Operations | 612.3 M | |||
| Earnings Per Share | 9.52 X | |||
| Price To Earnings To Growth | 3.36 X | |||
| Target Price | 412.2 | |||
| Number Of Employees | 11.93 K | |||
| Beta | 0.45 | |||
| Market Capitalization | 28.45 B | |||
| Total Asset | 5.07 B | |||
| Retained Earnings | 462 M | |||
| Working Capital | 122 M | |||
| Current Asset | 439 M | |||
| Current Liabilities | 317 M | |||
| Z Score | 16.2 | |||
| Annual Yield | 0 % | |||
| Five Year Return | 0.57 % | |||
| Net Asset | 5.07 B | |||
| Last Dividend Paid | 1.44 |
About Sartorius Stedim Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sartorius Stedim Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sartorius Stedim using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sartorius Stedim Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Sartorius Stedim
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sartorius Stedim position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sartorius Stedim will appreciate offsetting losses from the drop in the long position's value.Moving together with Sartorius Stock
| 0.61 | ALCAR | Carmat | PairCorr |
| 0.75 | AMPLI | Amplitude Surgical SAS | PairCorr |
Moving against Sartorius Stock
| 0.78 | ALCOF | Cofidur SA | PairCorr |
| 0.56 | ACA | Credit Agricole SA | PairCorr |
| 0.48 | AREIT | Altareit | PairCorr |
| 0.41 | AM | Dassault Aviation | PairCorr |
The ability to find closely correlated positions to Sartorius Stedim could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sartorius Stedim when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sartorius Stedim - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sartorius Stedim Biotech to buy it.
The correlation of Sartorius Stedim is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sartorius Stedim moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sartorius Stedim Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sartorius Stedim can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Sartorius Stedim Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Complementary Tools for Sartorius Stock analysis
When running Sartorius Stedim's price analysis, check to measure Sartorius Stedim's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sartorius Stedim is operating at the current time. Most of Sartorius Stedim's value examination focuses on studying past and present price action to predict the probability of Sartorius Stedim's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sartorius Stedim's price. Additionally, you may evaluate how the addition of Sartorius Stedim to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |